Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "SIFI"

264 News Found

Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
News | June 14, 2022

Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022

The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea


Diversification by pharma companies critical to repositioning supply chain
News | March 02, 2022

Diversification by pharma companies critical to repositioning supply chain

Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel


Singapore first to top WHO’s classification of medical regulator
News | March 01, 2022

Singapore first to top WHO’s classification of medical regulator

Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference


USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
Drug Approval | June 17, 2025

USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru

The inspection concluded successfully, with the facility found to be in compliance with the required regulations


Zydus receives EIR for the API manufacturing facility at Ankleshwar and Dabhasa
Drug Approval | June 12, 2025

Zydus receives EIR for the API manufacturing facility at Ankleshwar and Dabhasa

Zydus receives EIR for the API manufacturing facility at Ankleshwar


Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
News | June 02, 2025

Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients


Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
News | May 24, 2025

Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr

Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore


Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer
Diagnostic Center | May 23, 2025

Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%


Briefs: Dr. Reddy's Laboratories, Relonchem,  Shilpa Pharma Lifesciences and Shanmuga Hospital
News | May 18, 2025

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA


Briefs: Zydus and CuraTeQ Biologics
Drug Approval | May 14, 2025

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA